Makhov P.; Sohn J.A.; Serebriiskii I.G.; Fazliyeva R.; Khazak V.; Boumber Y.; Uzzo R.G.; Kolenko V.M.
(2020)
© 2020, The Author(s), under exclusive licence to Cancer Research UK. Background: Multi-targeted tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). ...